PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

Francesco Passiglia, Giuseppe Bronte, Viviana Bazan, +8

Oncotarget

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Alessandro Russo, Marco Russano, Tindara Franchina, +28

Advances in Therapy

MedicineImmunologyHematologyPathologyImmune Checkpoint Inhibitor +7

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, +225

The Lancet Oncology

Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer +5

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

Francesco Passiglia, Antonio Galvano, Marta Castiglia, +10

Therapeutic Advances in Medical Oncology

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score

Antonio Galvano, Marta Peri, Aurelia Guarini, +11

Therapeutic Advances in Medical Oncology

Accuracy evaluation of orthodontic movements with aligners: a prospective observational study

Giuseppa Bilello, M. Fazio, E. Amato, +3

Progress in Orthodontics

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?

Oronzo Brunetti, Afshin Derakhshani, Behzad Baradaran, +3

Frontiers in Oncology

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus

Daniela Cabibi, Stefano Caruso, Viviana Bazan, +13

Oncotarget

Esophageal CancerImmunologyGastroenterologyPathologyNew Biomarkers +14

Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis

Francesco Passiglia, Sérgio Rizzo, Christian Rolfo, +9

Current Cancer Drug Targets

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups

Francesco Passiglia, Antonio Galvano, Valerio Gristina, +6

Translational Lung Cancer Research